The present invention relates to the use of sensing particles in gases, such as odors and/or volatile organic compounds (“VOCs”), and creating a feedback mechanism for various uses and applications.
There are many areas in which information feedback from gas analysis can be used for quality control and identification of persons, diseases, dangerous industrial and explosive materials, and monitoring human health conditions. Such use of odor and/or VOC detection can assist in quality control in manufacturing materials, including drugs and pharmaceuticals. As an example, Johnson & Johnson was required to recall medications as a result of chemical contamination that resulted in an off-odor to the medication. Odor feedback during the manufacturing process would have detected the presence of the odor early in the manufacturing cycle, thereby eliminating costly waste and assisting to maintain product integrity.
Another example is the use of odor and/or VOC detection for uniquely identifying an individual. This may be used at various points of entry and/or security check points. This may be used on various means of transportation (e.g., planes, ships and boats, buses, trains and automobiles). An example of the use of the technology for uniquely identifying an individual is by monitoring specific VOCs that are known to be genetically controlled. Examples of these VOCs include but are not limited to 3-methybutanal, 2-pentanone, Z-3-methyl-2-hexenoic acid, E-3-methyl-2-hexenoic acid, 7-octenoic acid, 3-hydroxy-3-methyl-hexanoic acid, 3-methybutyric acid, 2-methybutric acid, p-cresol, phenol, phenylacetic acid, octanal, nonanal, and decanal.
Another example is the use of odor and/or VOC detection for identifying a classification of an individual. This classification may be race, gender, family, tribe, and/or membership in specific communities.
Yet another example is the use of odor and/or VOC detection for determining if an individual or individuals have been exposed to a general class of materials, such as explosives or dangerous chemicals (e.g., nerve agents or other materials known as Chemical and Biological Warfare Agent threats).
A further example is the use of odor and/or VOC detection for identifying and/or classifying the relationship of an individual to an object. This may be used for forensic purposes, (e.g., providing information related to who may have worn clothing found at a crime scene).
Another example is the use of odor and/or VOC detection for monitoring human, animal, or plant health. The use of odor and/or VOC detection can be utilized to identify specific diseases in a person, such as, but not limited to, lung cancer or other cancers, diabetes, emphysema, or asthma.
Another example is the use of odor and/or VOC detection for promoting or improving marketing of products. An example may be to maintain a certain aroma in a room or area that would promote sales. The system may be a feedback loop between an odor and/or VOC producing mechanism and a sensor that monitors the amount of odor in a room or area, in order to maintain the odor and/or VOC level within a safe and desirable range. The intensity of the odor and/or VOC concentration may be varied from day-to-day or time of day (e.g., coffee in the morning, bacon at lunch, etc.). The type of odor or VOC may be selected to promote the marketing of certain produce (e.g., fresh tomatoes), or even of new homes or other real-estate (e.g., fresh baked cookie odor or vanilla odor).
A further example is the use of odor and/or VOC detection for theft control.
Another example is the use of odor and/or VOC detection for monitoring or controlling an industrial process, such as but not limited to doping an odorant into a gas stream.
Active infections have long been known to exude noxious odors. For at least the prior decade, the use of e-nose technologies (electronic odor sensors) have been proposed as a method of monitoring infected wounds. Such use of electronic odor sensors has not been successful because an instrument was not available to detect the foul odors. And for low level infections or for mere colonizations of bacteria in wounds, there were not enough of the VOCs (volatile organic compounds) produced for electronic odor sensors, nor human noses, to detect them. In the case of sessile bacteria, typically embedded in a biofilm, or pathogens present only in spore form, the VOCs of active bacterial metabolism may not be present at all.
Electronic odor sensors require a vaporous sample to process. Without VOCs available, even a maximally sensitive electronic odor sensor will fail to detect the bacteria. It is now well known that chronic wounds are caused by bacteria embedded in biofilms of their own manufacture (James, G. A. “Biofilms in chronic wounds,” Wound Rep Regen, 2007). It is the sessile and/or quiescent pathogens in wound beds that drive the chronicity of intransigent wounds and therefore of importance for achieving lower costs and improving outcomes in wound care. The biofilm protects the bacteria from endogenous and exogenous antimicrobial attack, but also limits the metabolic activity of the bacteria. This screens the presence of the bacteria from normal detection by their emitted odors or fluids. What is needed is a mechanism that will liberate characteristic VOC signatures for positive detection of the presence of these bacteria or their vegetative byproducts.
A solution is to apply a physical or chemical challenge to the tissues in which the suspected bacteria are contained. Such a challenge will stimulate, excite, liberate, or generate VOCs that are detected by an electronic odor sensor (also referred to herein as an “e-nose”). In the same way that crushing a mint leaf releases its scent, performing interventions on wounds will produce odors that can be electronically analyzed.
More specifically, wounds are cleansed to remove dead tissue and exudates, known clinically as debridement. The cleansing process may involve blades, abrading devices, chemical cleansers, or advanced chemo-mechanical cleaning such as with ultrasound or plasmas. Blades will atomize substrate tissues and thereby mechanically generate vapors that can be sensed. Abrasion will likewise atomize substrate tissues liberating odors. Chemical cleansers cause reactions in the tissue surface, generally oxidations, which will produce signature vapors. And the advanced cleansing modalities will act in both ways to produce signature vapors.
Embodiments of the present invention may be in the form of a sampling port attached to the wound care site or tool in use to perform the intervention(s). In the case of a debridement blade, a sampling line may be integrated in the scalpel handle. In the case of cleansers, a sampling line may be attached to the patient's skin in the near vicinity of the wound, or to cleanser-dispensing applicators. In the case of advanced debridement modalities, they may involve an applicator handle similar to blade handles, and also include cabling or plumbing that routes to and from an active console that contains the generators of plasma, ultrasound, water mist, etc. Such cabling/plumbing would allow for easy incorporation of a sampling system for odor analysis.
It is also important to note that the application of energy or chemicals to tissues may create new chemical signature vapors, i.e., vapors not natively present in the targeted tissues. These new components can be uniquely specific to the targeted condition. For example, with application of peroxide cleansers, the free-radical reactions with fatty acids and lipopolysaccharides of biofilms will generate oxidized small molecules that are indicators of the presence of biofilms.
An aspect of this disclosure is the use of odor and/or VOC detection for monitoring the progress of cutting or ablation mechanisms used to remove damaged, diseased and/or dead human matter such as flesh or bone matter. For example, this tool may be used to monitor the progress of removing or treating tissue using a debridement tool. By monitoring the odors resulting from the debridement process, one can determine when the damaged tissue has been removed or that the tool is removing healthy tissue (i.e., a sort of end-point detector).
Herein, the terms “air,” “gas,” and “vapor” are used interchangeably to refer to the volume of gas containing analytes (particles) sensed by an e-nose device. Additionally, the e-nose may be used to detect such analytes (particles) dissolved in a liquid fluid.
For embodiments disclosed herein, levels of detection may be in a percent concentration range (e.g., breath analysis for measuring breath alcohol levels), or down to very minute levels such as parts per trillion (e.g., for disease detection or uniquely identifying an individual or industrial process control).
Referring to
Referring to
The VOC analyte molecules are ionized as they enter the DMS 305. One technique used to create gas ions is to place a radioactive source material 701 (either beta emitter or alpha emitter) next to the gas flow 601 and 602. Alternatively, an ion generator that does not utilize radioactive sources may be utilized (see
The gas sample is separated by the DMS filter 305 to further improve the analyte identification. By carefully calibrating the tool for the chemicals of interest, the analyte concentrations in the gas sample are known. Once the analytes and their concentrations have been identified, the data is further analyzed for the desired purpose. In another analysis method, the identification details may be compared to a previously determined database of compounds and concentration ratios seen with known disease conditions to determine disease status. In the case of wound debridement, this would be conditions of infection and biofilm presence as determined to be present by standard methods and clinical experts. Alternative analyses of compounds identified may be performed by pattern recognition methods such as principal component mapping, k-nearest neighbor classification, or neural network recognition. The analyte identification step may be alternatively bypassed and the system simply map disease conditions to the signal output of the DMS filter. This has an advantage of not requiring detailed calibration of the tool for specific chemical identifications, but produces no intermediate information for verification of the biochemical identity of the targeted disease condition.
The DMS is essentially an ion filter operating in a gas environment. The gas environment may be filtered and dried (de-humidified) air at near atmospheric pressure. Other gasses may be used such as high purity nitrogen, argon or other noble gasses. A principle of operation of the DMS is illustrated in
As stated previously, DMS is one of a family of Ion Mobility Spectrometry (IMS) tools that has several advantages compared to standard time-of-flight IMS approaches. Mainly it provides a richer set of data and improves on the chemical selectivity while maintaining sensitivity. Gas chromatography coupled with differential mobility spectrometry (GC/DMS) has a number of advantages.
A physical principle of DMS is based upon the relationship of an ion's velocity in a gas being proportional to an applied electric field strength, or
{right arrow over (v)}
i({right arrow over (E)})=ki({right arrow over (E)}){right arrow over (E)}
where ki(E) is the ion mobility.
ki(E) depends on the carrier gas pressure, composition and temperature as well, but those variables can be fixed by design. The DMS takes advantage of the non-constant and non-linear electric field dependence of the ion mobility. Referring to
Another electronic odor sensor embodiment is Ion Mobility Spectrometry (“IMS”). IMS is similar to DMS with a difference. IMS essentially uses a time-of-flight (“TOF”) measurement to measure how fast a given ion is able to move through a uniform electric field at a given pressure/atmosphere. DMS does not rely on a TOF, but instead uses the differences in mobility of different ions to detect only the ion as it passes through an ion filter.
Another electronic odor sensor embodiment is gas chromatograph mass spectrometry (“GC/MS”). GC/MS systems are sensitive and capable of identifying the constituents of a large number of unique combinations of VOCs signatures to diagnose many different types of diseases. However, a drawback to this technology is in the lengthy operating times, cost, and size. GC/MS systems may cost approximately $75K-$150K. In addition, GC/MS systems require vacuum pumps, which may limit miniaturization and increase power consumption. In contrast, DMS technology has advantages for portable applications and can achieve the required sensitivity.
Another electronic odor sensor embodiment is a quartz microbalance (“QBM”). This technology relies on the change in resonant frequency of a micromachined quartz beam when the molecules of a desired analyte adsorb onto it, thus changing the resonant mass. These beams are patterned with special coatings, such as metalloporphyrin complexes to selectively capture molecules of interest. To detect multiple analytes simultaneously, arrays of these sensors are used, making it more difficult to fabricate as well as implement for odor analysis, as this requires complex analysis algorithms. QMB technologies have some advantages for certain applications, but the sensitivities are insufficient compared to IMS, DMS, or GC/MS technologies, which may be necessary for many applications. The limit of detection for QBM is in the parts per million range and more recently into the hundreds of parts per billion range.
Another electronic odor sensor embodiment is colorimetric sensors. These sensors may be two-dimensional arrays of chemically active “spots.” Each spot is sensitive to one type of chemical, which is made sensitive by impregnating a disposable cartridge with a chemically sensitive compound that changes color when bound to the analyte to be detected. The chemically sensitive compounds may be metalloporphyrins as well as other materials. The gas is flowed across the sensor, and the changes in color are detected by an optical scanner or camera system, which analyzes and quantifies the detection. These sensors have achieved only moderate success due to the lack of sensitivity and the limited number of spots on the sensor.
Another electronic odor sensor embodiment is conducting polymers. Conductive polymer-based gas sensors are a relatively mature technology and are based on the change in conductance of an organic polymer in the presence of selected analytes. These conductive polymers may be patterned in thin layers over electrodes, which are connected to electronics that sense a change in resistance of the material when exposed to the desired analyte. Scensive Technologies Limited, a company in the United Kingdom started in 1995, has been developing a sensor platform referred to as the Bloodhound, which they claim can detect down to parts per million and parts per billion levels. The Bloodhound and similar e-nose approaches have more difficulty separating out specific analytes, since the sensors in the array are not uniquely sensitive to those compounds and will be confounded by cross-sensitivity to other analytes.
An alternative odor sensor embodiment is surface acoustic wave (SAW) analysis in which compounds are adsorbed onto a thermally controlled piezoelectric crystal. By altering the temperature of the crystal, or by applying a chemically absorptive coating, various compounds can be made to condense or adsorb on the surface of the crystal, thereby providing specificity. In order to simultaneously detect multiple analytes, the crystal is either swept across an appropriate range of temperatures, which is slow, or is duplicated at multiple temperatures, which increases the complexity and cost of the analyzer. The chemically absorptive coating approach limits single devices to detecting only compounds attracted by the coating, and specificity is controlled by the chemistry of the coating-compound interaction.
An alternative analysis configuration is to attach a sampling trap to the debriding tool or patient's skin, and then send the trap to a remote analyzer for odor analysis post de facto. Technically more complex would be an integrated analyzer directly within the tool or on the skin of the patient. Because odors disperse within an air volume, the sampling might be arranged within the treatment room and simply sample room air following interventions, which release the odors to be analyzed.
This application claims priority to U.S. Provisional Patent Applications Ser. Nos. 61/534,025 and 61/583,288, which are hereby incorporated by reference herein.
Number | Date | Country | |
---|---|---|---|
61534025 | Sep 2011 | US | |
61583288 | Jan 2012 | US |